3,649 Stryker Corporation $SYK Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp trimmed its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 1.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 289,940 shares of the medical technology company's stock after selling 3,649 shares during the period. Boston Trust Walden Corp owned 0.08% of Stryker worth $79,847,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Gables Capital Management Inc. purchased a new stake in shares of Stryker during the second quarter worth about $25,000. Kilter Group LLC acquired a new position in shares of Stryker during the 2nd quarter worth about $25,000. Highland Investment Advisors LLC purchased a new position in Stryker in the 2nd quarter valued at about $25,000. Cornerstone Financial Management LLC lifted its stake in Stryker by 66.0% in the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company's stock valued at $25,000 after buying an additional 31 shares in the last quarter. Finally, Compass Financial Management LLC acquired a new stake in Stryker in the 2nd quarter worth about $27,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Buying and Selling at Stryker

In other news, insider Dylan Crotty sold 441 shares of the business's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider directly owned 6,102 shares in the company, valued at $2,005,178.22. The trade was a 6.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 50,000 shares of the company's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the sale, the director owned 2,251,375 shares of the company's stock, valued at $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 351,267 shares of company stock worth $118,197,701. Insiders own 4.60% of the company's stock.

Stryker Price Performance

Shares of NYSE SYK opened at $340.39 on Thursday. The firm has a 50-day simple moving average of $292.21 and a 200-day simple moving average of $323.91. The company has a quick ratio of 1.30, a current ratio of 2.18 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $129.59 billion, a price-to-earnings ratio of 36.25, a price-to-earnings-growth ratio of 2.13 and a beta of 0.78. Stryker Corporation has a 52 week low of $267.00 and a 52 week high of $389.33.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing analysts' consensus estimates of $3.55 by ($0.03). Stryker had a return on equity of 23.74% and a net margin of 13.78%. The business had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.62 billion. During the same quarter in the previous year, the firm posted $3.19 earnings per share. The business's revenue was up 7.6% compared to the same quarter last year. On average, equities analysts predict that Stryker Corporation will post 14.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on SYK. Evercore boosted their price objective on Stryker from $335.00 to $355.00 in a research note on Wednesday, October 28th. JPMorgan Chase & Co. reduced their target price on Stryker from $350.00 to $340.00 and set an "overweight" rating for the company in a report on Friday, October 30th. Sanford C. Bernstein restated a "market perform" rating on shares of Stryker in a research report on Wednesday, October 7th. Deutsche Bank Aktiengesellschaft lowered their price target on Stryker from $315.00 to $275.00 and set a "hold" rating on the stock in a research note on Friday, October 30th. Finally, The Goldman Sachs Group lowered their price target on Stryker from $363.00 to $339.00 and set a "neutral" rating on the stock in a research note on Tuesday, July 14th. Twenty-one equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $343.73.

Stryker Profile

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.